Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Lambert LA. Looking up: recent advances in understanding and treating peritoneal carcinomatosis. CA Cancer J Clin. 2015;65(4):284–98.

Chan CH, Cusack JC, Ryan DP. A critical look at local-regional management of peritoneal metastasis. Hematol Oncol Clin North Am. 2015;29(1):153–8.

Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–63.

Economou SG, Mrazek R, McDonald G, Slaughter D, Cole WH. The intraperitoneal use of nitrogen mustard at the time of operation for cancer. Ann N Y Acad Sci. 1958;68(3):1097–102.

Ceelen W, Levine EA, editors. Intraperitoneal cancer therapy: principles and practice. Boca Raton: CRC Press; 2016.

Chia CS, You B, Decullier E, Vaudoyer D, Lorimier G, Abboud K, Bereder JM, Arvieux C, Boschetti G, Glehen O; BIG RENAPE Group. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol. 2016;[Epub ahead of print]

Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol. 2012;13(8):e362–9.

Beckert S, Struller F, Grischke EM, Glatzle J, Zieker D, Königsrainer A, Königsrainer I. Surgical management of peritoneal surface malignancy with respect to tumour type, tumour stage and individual tumour biology. Zentralbl Chir. 2013;[Epub ahead of print] German.

Marmor RA, Kelly KJ, Lowy AM, Baumgartner JM. Laparoscopy is safe and accurate to evaluate peritoneal surface metastasis prior to cytoreductive surgery. Ann Surg Oncol. 2016;23(5):1461–7.

Reymond MA, Hu B, Garcia A, Reck T, Köckerling F, Hess J, Morel P. Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator. Surg Endosc. 2000;14(1):51–5.

Tempfer CB, Winnekendonk G, Solass W, et al. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study. Gynecol Oncol. 2015;137(2):223–8.

Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg. 2016;20(2):367–73.

Demtröder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal Dis. 2016;18(4):364–71.

Blanco A, Giger-Pabst U, Solass W, Zieren J, Reymond MA. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2013;20(7):2311–6.

Odendahl K, Solass W, Demtröder C, Giger-Pabst U, Zieren J, Tempfer C, Reymond MA. Quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Eur J Surg Oncol. 2015;41(10):1379–85.

Parsons J. Ellery B. Pressurised intraperitoneal aerosol chemotherapy. Technology Brief. Health Policy Advisory Committee on Technology. State of Queensland, Australia, June 2015. https://www.health.qld.gov.au/healthpact/docs/briefs/WP223.pdf . Accessed date 30 Jun 2016.

Study of efficacy and safety of laparoscopic intra-abdominal chemotherapy (PIPAC) performed in patients with peritoneal carcinomatosis from colorectal, ovarian, gastric cancer and primary peritoneal tumors (PI-CaP). NCT0260478, www.clinicaltrials.gov . Accessed date 22 Feb 2016.

Treating peritoneal carcinomatosis with PIPAC, NCT02320448, www.clinicaltrials.gov . Accessed date 22 Feb 2016.

Intraperitoneal aerosol chemotherapy in gastric cancer (PIPAC-GA01), NCT01854255, www.clincialtrials.gov . Accessed date 22 Feb 2016.

Efficacy and safety of PIPAC/PITAC in gastric, ovarian, colorectal cancer and mesothelioma with pleural carcinomatosis. (PIPAC/PITAC), NCT02720835, www.clincialtrials.gov . Accessed date 18 Apr 2016.

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) applied to first platinum-resistant recurrence of ovarian tumor (PARROT), NCT02735928, www.clincialtrials.gov . Accessed date 18 Apr 2016.

A study with intraperitoneal cisplatin and doxorubicin in recurrent ovarian cancer and peritoneal carcinomatosis. NCT02475772, www.clincialtrials.gov . Accessed date 18 Apr 2016.

Solaß W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc. 2012;26(7):1849–55.

Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005;2(1):3.

Solass W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol. 2013;20(11):3504–11.

Demtröder C, Solass W, Winnekendonk G, Tempfer C, Reymond MA. Electrostatic precipitation pressurized intraperitoneal aerosol chemotherapy (ePIPAC): first in-human application. Pleura Peritoneum.2016;1:109–16.

Königsrainer I, Beckert S. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: where are we? World J Gastroenterol. 2012;18(38):5317–20.

Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–72.

Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42.

Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949, p. 196.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12:19–23.

Solass W, Sempoux C, Detlefsen S, Carr NJ, Bibeau F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS). Pleura Peritoneum. 2016;1(2):99–108.

Königsrainer I, Horvath P, Struller F, Königsrainer A, Beckert S. Initial clinical experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in signet-ring cell gastric cancer with peritoneal metastases. J Gastric Cancer. 2014;14(2):117–22.

Pelz JO, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;1;99(1):9–15.

Khomyakov V, Ivanov A, Ryabov A, Bolotina L, Utkina A, Volchenko N, Kaprin A. Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and doxorubicin administered as a pressurized aerosol: an open-label, phase-2 study (PIPAC-GA2). Pleura Peritoneum. in press.

Gill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011;104:692–8.